Mannosamine-Modified Poly(lactic-co-glycolic acid)-Polyethylene Glycol Nanoparticles for the Targeted Delivery of Rifapentine and Isoniazid in Tuberculosis Therapy DOI

Cong Peng,

Haopeng Luan,

Qisong Shang

и другие.

Bioconjugate Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Апрель 22, 2025

Tuberculosis, caused by Mycobacterium tuberculosis, is the leading cause of mortality attributed to a single infectious agent. Following macrophage invasion, M. tuberculosis uses various mechanisms evade immune responses and resist antituberculosis drugs. This study aimed develop targeted drug delivery system utilizing mannosamine (MAN)-modified nanoparticles (NPs) composed poly(lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG), loaded with rifapentine isoniazid, enhance macrophage-directed therapy bacterial elimination. PLGA-PEG copolymer was modified through an amidation reaction. Rifapentine- isoniazid-loaded PLGA-PEG-MAN NPs were synthesized using double emulsion solvent evaporation technique. The exhibited average particle size 117.67 nm displayed favorable physicochemical properties without evidence cellular or hemolytic toxicity. loading rates 11.73% for 5.85% isoniazid. Sustained release achieved over period exceeding 72 h, antibacterial activity remaining intact during encapsulation. Synergistic bactericidal effects noted. Additionally, mannosamine-modified enhanced phagocytic macrophages via mannose receptor-mediated endocytosis, thereby improving efficiency significantly boosting efficacy within macrophages. Pathological staining biochemical analysis rat organs following intravenous injection indicated that did not any significant toxic side in vivo. findings this indicate isoniazid represent promising targeting antitubercular therapy.

Язык: Английский

Mannosamine-Modified Poly(lactic-co-glycolic acid)-Polyethylene Glycol Nanoparticles for the Targeted Delivery of Rifapentine and Isoniazid in Tuberculosis Therapy DOI

Cong Peng,

Haopeng Luan,

Qisong Shang

и другие.

Bioconjugate Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Апрель 22, 2025

Tuberculosis, caused by Mycobacterium tuberculosis, is the leading cause of mortality attributed to a single infectious agent. Following macrophage invasion, M. tuberculosis uses various mechanisms evade immune responses and resist antituberculosis drugs. This study aimed develop targeted drug delivery system utilizing mannosamine (MAN)-modified nanoparticles (NPs) composed poly(lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG), loaded with rifapentine isoniazid, enhance macrophage-directed therapy bacterial elimination. PLGA-PEG copolymer was modified through an amidation reaction. Rifapentine- isoniazid-loaded PLGA-PEG-MAN NPs were synthesized using double emulsion solvent evaporation technique. The exhibited average particle size 117.67 nm displayed favorable physicochemical properties without evidence cellular or hemolytic toxicity. loading rates 11.73% for 5.85% isoniazid. Sustained release achieved over period exceeding 72 h, antibacterial activity remaining intact during encapsulation. Synergistic bactericidal effects noted. Additionally, mannosamine-modified enhanced phagocytic macrophages via mannose receptor-mediated endocytosis, thereby improving efficiency significantly boosting efficacy within macrophages. Pathological staining biochemical analysis rat organs following intravenous injection indicated that did not any significant toxic side in vivo. findings this indicate isoniazid represent promising targeting antitubercular therapy.

Язык: Английский

Процитировано

0